LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Список акций・Lisata Therapeutics

L
Lisata Therapeutics

Открыт

4.57 0.22

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

4.5600000000000005

Макс.

4.58

Ключевые показатели
By Trading Economics
Сотрудники	26

Дивиденды
By Dow Jones
Следующий отчет о доходах	26 февр. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	14M 34M
Предыдущая цена открытия	4.35
Предыдущая цена закрытия	4.57

Lisata Therapeutics График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

15 февр. 2026 г., 23:21 UTC

Приобретения, слияния, поглощения

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 февр. 2026 г., 23:45 UTC

Обсуждения рынка

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 февр. 2026 г., 23:40 UTC

Обсуждения рынка

Gold Falls on Possible Position Adjustments -- Market Talk

15 февр. 2026 г., 23:06 UTC

Отчет

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 февр. 2026 г., 23:04 UTC

Отчет

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 февр. 2026 г., 23:04 UTC

Отчет

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 февр. 2026 г., 23:01 UTC

Отчет

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 февр. 2026 г., 23:01 UTC

Отчет

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 февр. 2026 г., 22:53 UTC

Приобретения, слияния, поглощения

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 февр. 2026 г., 22:53 UTC

Приобретения, слияния, поглощения

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 февр. 2026 г., 22:52 UTC

Приобретения, слияния, поглощения

Qube Shareholders to Receive A$5.20/Share in Cash

15 февр. 2026 г., 22:52 UTC

Приобретения, слияния, поглощения

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 февр. 2026 г., 22:22 UTC

Приобретения, слияния, поглощения

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 февр. 2026 г., 22:17 UTC

Приобретения, слияния, поглощения

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 февр. 2026 г., 22:16 UTC

Приобретения, слияния, поглощения

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 февр. 2026 г., 22:14 UTC

Приобретения, слияния, поглощения

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 февр. 2026 г., 22:14 UTC

Приобретения, слияния, поглощения

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 февр. 2026 г., 20:48 UTC

Отчет

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 февр. 2026 г., 20:47 UTC

Отчет

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 февр. 2026 г., 20:46 UTC

Отчет

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 февр. 2026 г., 20:45 UTC

Отчет

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 февр. 2026 г., 20:44 UTC

Отчет

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 февр. 2026 г., 20:44 UTC

Отчет

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 февр. 2026 г., 20:43 UTC

Отчет

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 февр. 2026 г., 20:42 UTC

Отчет

BlueScope Net Debt A$2.2 Million at Dec. 31

15 февр. 2026 г., 20:42 UTC

Отчет

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 февр. 2026 г., 20:41 UTC

Отчет

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 февр. 2026 г., 20:40 UTC

Отчет

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 февр. 2026 г., 20:40 UTC

Отчет

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 февр. 2026 г., 20:39 UTC

Отчет

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Сравнение c конкурентами

Изменение цены

Lisata Therapeutics Прогноз

Консенсус по рейтингу

By TipRanks

Нейтрально

1 ratings

Покупка

Удержание

Продажа

Основано на мнении 1 аналитиков, присваивавших рейтинги акциям Lisata Therapeutics – Данные за последние 3 месяца.

Финансовые показатели

О компании Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.